Please ensure Javascript is enabled for purposes of website accessibility

Why Investors Weren't Excited About Illumina's Q3 Earnings Beat

By Keith Speights - Oct 25, 2019 at 5:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The gene-sequencing pioneer beat Wall Street revenue and earnings estimates and raised its full-year earnings outlook. But it wasn't enough to make investors happy.

Illumina (ILMN -0.53%) downright disappointed investors with its second-quarter results in July, reporting slowing revenue growth and a year-over-year decline in adjusted earnings. However, CEO Francis deSouza said at the time that this wasn't "a new normal" for the gene-sequencing leader.

The company proved deSouza right -- sort of -- when it announced its third-quarter results after the market closed on Thursday. But it was also clear that Illumina hasn't yet returned to its "old normal" of sizzling revenue growth.

DNA helix on blue background

Image source: Getty Images.

The key numbers

Illumina reported Q3 revenue of $907 million, up 6% year over year. This figure was much higher than the consensus analysts' revenue estimate of $870.8 million. 

The company announced net income in the third quarter of $234 million, or $1.58 per diluted share, based on generally accepted accounting principles (GAAP). This reflected a significant improvement from the prior-year period GAAP earnings of $199 million, or $1.33 per share.

Illumina posted adjusted earnings of $286 million, or $1.93 per diluted share. This was a huge jump from the adjusted earnings of $227 million, or $1.52 per share, reported in the same quarter last year. It also trounced the average Wall Street analysts' earnings estimate of $1.40 per share.

The company generated operating cash flow of $267 million and free cash flow of $218 million in the third quarter. Both figures reflected declines from the prior-year period. Illumina ended Q3 with cash, cash equivalents, and short-term investments totaling $3.2 billion.

Behind those numbers

The company beat Wall Street estimates on both the top and bottom lines by a lot. Were investors excited? Not really. It was more of an indication that analysts were too pessimistic than a reason to celebrate Illumina's performance. Although Francis deSouza said that Q3 "was a solid quarter for Illumina," he added that the company's product revenue was in line with the company's own internal expectations.

The reality is that Illumina remains well off-track from being the growth stock that it once was. Probably the main culprit is the company's microarray business, with revenue falling nearly 24% year over year and 7% quarter over quarter, to $102 million. Weakness in the direct-to-consumer personal genomics business continued to weigh on the company.

Instrument sales also slipped nearly 6% from the prior-year period, to $146 million. The good news, though, was that this represented a jump of close to 10% from the second quarter.

Illumina's bottom line improved nicely, as well, thanks mainly to the company keeping a lid on spending. Operating expenses declined nearly 5% year over year, to $340 million. The company also benefited from lower income taxes in the third quarter of 2019, compared to the same quarter a year ago.

Looking ahead

Illumina maintained its full-year 2019 revenue guidance of year-over-year revenue growth of around 6%. However, the company raised its full-year earnings outlook. Illumina now projects GAAP earnings per share of between $6.55 and $6.60, up from its previous guidance of between $6.41 and $6.51. It also expects adjusted earnings per share between $6.40 and $6.45, higher than the earlier projection of non-GAAP earnings per share between $6 and $6.10.

Perhaps the biggest question now for Illumina is what will happen with its planned acquisition of Pacific Biosciences of California. The United Kingdom's Competition and Markets Authority (CMA) announced today a provisional decision that would block the deal, based on concerns that it would limit competition in the gene-sequencing market.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$186.43 (-0.53%) $-1.00
Pacific Biosciences of California, Inc. Stock Quote
Pacific Biosciences of California, Inc.
PACB
$4.57 (-5.97%) $0.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.